Recent data on cannabinoids and their pharmacological implications in neuropathic pain
- PMID: 20108515
- PMCID: PMC5654208
Recent data on cannabinoids and their pharmacological implications in neuropathic pain
Abstract
Natural cannabinoids have been used for centuries for their psychotropic properties, but their possible therapeutic implications in analgesia have been recently documented. The present review intended to make an analysis of the neuroanatomy and physiology of the cannabinoid system (receptors, functions, agents acting on these receptors) and of its implications in neuropathic pain. There were also described the complex phenomena implicated in the generation and maintenance of neuropathic pain, by high lightening the implications of endogenous cannabinoids in this complex of painful conditions. The pharmacological analgesia test proves of cannabinoid implication in neuropathic pain was sustained by many studies presented in this paper. Therapeutic approaches using natural and synthetic cannabinoid receptor agonists were reviewed. Therapeutic perspectives in neuropathic pain might involve the development of new agents that influence the cannabinoid system. Thus, peripheral acting cannabinoid 1 receptors agonists, selective cannabinoid 2 receptor agonists and also modulators of endocannabinoids metabolism might be a way to success in the treatment of this complex entity called neuropathic pain.
Similar articles
-
[The cannabinoid system and pain: towards new drugs?].J Soc Biol. 2009;203(1):99-106. doi: 10.1051/jbio:2009002. Epub 2009 Apr 10. J Soc Biol. 2009. PMID: 19358815 Review. French.
-
Cannabinoid 1 (CB1) receptor--pharmacology, role in pain and recent developments in emerging CB1 agonists.CNS Neurol Disord Drug Targets. 2011 Aug;10(5):536-44. doi: 10.2174/187152711796235005. CNS Neurol Disord Drug Targets. 2011. PMID: 21631407 Review.
-
Cannabinoid mechanisms of pain suppression.Handb Exp Pharmacol. 2005;(168):509-54. doi: 10.1007/3-540-26573-2_17. Handb Exp Pharmacol. 2005. PMID: 16596786 Review.
-
Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40. doi: 10.1517/13543784.2014.918603. Epub 2014 May 16. Expert Opin Investig Drugs. 2014. PMID: 24836296 Review.
-
Use of cannabinoids as a novel therapeutic modality against autoimmune hepatitis.Vitam Horm. 2009;81:487-504. doi: 10.1016/S0083-6729(09)81019-4. Vitam Horm. 2009. PMID: 19647124 Free PMC article. Review.
Cited by
-
Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.Br J Pharmacol. 2011 Mar;162(6):1439-52. doi: 10.1111/j.1476-5381.2010.01156.x. Br J Pharmacol. 2011. PMID: 21175569 Free PMC article.
-
Cannabinoid system and cyclooxygenases inhibitors.J Med Life. 2011 Jan-Mar;4(1):11-20. Epub 2011 Feb 25. J Med Life. 2011. PMID: 21505570 Free PMC article. Review.
References
-
- Mechoulam R, Hanus L. A historical overview of chemical research on cannabinoids. Chem Phys Lipids. 2000 Nov;108(1-2):1–13. - PubMed
-
- Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002 Jun;54(2):161–202. - PubMed
-
- Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988 Nov;34(5):605–613. - PubMed
-
- Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 Aug ;346(6284):561–564. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical